Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99)...

Full description

Bibliographic Details
Main Authors: Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-45358-0

Internet

https://doi.org/10.1038/s41467-024-45358-0

Similar Items